LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test’s ongoing development and future launch into developing countries

LumiraDx has received $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test’s ongoing development and future launch into developing countries. The point of care molecular test is designed to fill gaps in the TB testing market and significantly increase access to testing.

More information

Details

London SE1 2AQ, UK

LumiraDx

Keywords

Molecular diagnostic test kits

Associated Trend items

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa

London, UK [November 14, 2022] LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced the continued commercial expansion of its HbA1c test, for professional use across multiple care settings. Used alongside the LumiraDx Platform, the test monitors known diabetic patients’ HbA1c levels and also serves as an aid in screening a...

More information

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay that can aid in the diagnosis of congestive heart failure (CHF)

The LumiraDx NT-proBNP direct fingerstick assay monitors levels of peptides elevated in the majority forms of heart failure and provides results in twelve minutes from sample application. It is designed to provide lab comparable performance in community-based healthcare settings to quickly and accurately aid in the diagnosis of individuals suspected of having congestive ...

More information

Boots UK announce plans to pilot a diabetes screening service powered by the LumiraDx HbA1c Test

The Boots Diabetes Screening Service

National pharmacy retail chain, Boots, recently announced a UK wide diabetes screening pilot which will offer a private screening service to customers using the LumiraDx Platform and HbA1c test. The pilot, which will launch in May in seven Boots stores, including: Manchester, London and Birmingham, will initially target cities with a higher prevalence of type 2 diabetes...

More information

Compare

Remove all

Compare up to 10 products